MoonLake Immunotherapeutics AG

https://www.moonlaketx.com

LinkedIn: https://www.linkedin.com/company/moonlake-immunotherapeutics-ag

MoonLake Immunotherapeutics AG, founded in 2021, is a clinical-stage biopharmaceutical company leveraging Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics has a portfolio of therapeutic programs based on Sonelokimab (M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. *

	Start	2021-01-01 established (approx)
	Industry	sonelokimab (M1095/ALX-0761) (IL-17 A/F Nanobody) (MoonLake / Avillion / Merck (DE) / Ablynx)
	Industry 2	drug development
	Person	Santos da Silva, Jorge P. (MoonLake 202107– CEO before nearly 15 years at McKinsey)
	Person 2	Bodenstedt, Matthias (MoonLake 202107– CFO before McKinsey)

	Region	Zug ZG
	Country	Switzerland
	Street	29 Dorfstr.
	City	6300 Zug ZG
		Address record changed: 2023-06-28

Basic data	Employees	B: 11 to 50 (2022-12-31)
	Currency	USD
	Profit	-64,506,051,000 (2022-12-31)
	Cash	72,114,735,000 (2022-12-31)

		* Document for »About Section«: MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug.

		Record changed: 2023-08-30

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]